3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
8
Breast Neoplasms
8
Vitamin D Deficiency
7
Polycystic Ovary Syndrome
4
Leukemia, Lymphocytic, Chronic, B-Cell
3
Warts
2
Rectal Neoplasms
2
Osteoporosis
2
Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Stroke
1
Spinal Cord Injuries
1
Seizures
1
Psoriasis
1
Prostate Adenocarcinoma
1
Polyps
1
Pathologic Processes
1
Pain
1
Ovarian Neoplasms
1
Osteoarthritis
1
Obesity
1
Neoplasms by Site
1
Myelodysplastic Syndromes
1
Meningitis
1
Melanoma, Cutaneous Malignant
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Interventions
Rituximab
67
Cyclophosphamide
52
fludarabine phosphate
44
Whole-Body Irradiation
36
Mycophenolic Acid
33
Peripheral Blood Stem Cell Transplantation
29
Tacrolimus
27
Busulfan
24
Cyclosporine
21
Antilymphocyte Serum
21
Melphalan
18
Filgrastim
16
Etoposide
15
Methotrexate
14
Radiotherapy
12
Lenalidomide
12
Cord Blood Stem Cell Transplantation
12
fludarabine
10
Sirolimus
10
Granulocyte Colony-Stimulating Factor
10
Dexamethasone
9
Bendamustine Hydrochloride
9
Prednisone
8
Bortezomib
8
thymoglobulin
7
idelalisib
7
Flow Cytometry
7
Calcium Dobesilate
7
ibritumomab tiuxetan
6
Methylprednisolone
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Lymphoma, B-Cell, Marginal Zone
×
Cholecalciferol
×
Clear all
NCT03078855
2024-09-04
ILyAD
University of Rochester
Phase 3
Completed
211 enrolled
13 charts